- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Idelalisib, Rituximab
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Long Beach, California • Fort Myers, Florida • Baltimore, Maryland + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 9,907
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Hot Flashes
- Interventions
- FP-101, Placebo Comparator
- Drug
- Lead sponsor
- Fervent Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 12
- States / cities
- Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 9 more
- Conditions
- Sensitivity, Contact
- Interventions
- ATx201, ATx201 Placebo Gel
- Drug
- Lead sponsor
- UNION therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
- Interventions
- vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiac Allograft Vasculopathy, Antibody Mediated Rejection
- Interventions
- Optical Coherence Tomography, Acetylcholine, Brachial Artery Flow Mediated Dilation
- Device · Drug · Procedure
- Lead sponsor
- Gladwin, Mark, MD
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Migraine, Migraine With or Without Aura
- Interventions
- Meditation
- Behavioral
- Lead sponsor
- Maharishi International University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Multiple Sclerosis
- Interventions
- Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
- Interventions
- Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
- Radiation · Drug
- Lead sponsor
- Benjamin Spieler
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Vascular Closure
- Interventions
- Femoral Venous Vascular Closure
- Device
- Lead sponsor
- Cardiva Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Luis Obispo, California + 12 more
- Conditions
- MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- MR exam, US exam, Blood draw, Physical measurements, Questionnaires
- Diagnostic Test · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 9 Years to 18 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Influenza Vaccination
- Interventions
- Fact Only Education Message, Fact and Myth Educational Message, Fact, Myth, Why Educational Message, Control Educational Message
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Venetoclax, cBTKi Monotherapy
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 20
- States / cities
- Springdale, Arkansas • Aurora, Colorado • Jacksonville, Florida + 17 more
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Durvalumab, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alcohol Use Disorder (AUD), PTSD
- Interventions
- Psilocybin 25 mg, Maltodextrin (Placebo)
- Drug
- Lead sponsor
- Nathan Brashares Sackett
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab ozogamicin, Dasatinib, Dexamethasone, Methotrexate, Vincristine, Ponatinib, Purinethol (6-Mercaptopurine), Prednisone
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
- Interventions
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2033
- U.S. locations
- 30
- States / cities
- Duarte, California • Glendale, California • Los Angeles, California + 25 more
- Conditions
- Lymphoma, Follicular
- Interventions
- Bendamustine, Rituximab, Y-90 ibritumomab
- Drug · Radiation
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 4
- States / cities
- Scarborough, Maine • Lebanon, New Hampshire • Durham, North Carolina + 1 more
- Conditions
- Paraesophageal Hernia, Large Hiatal Hernia
- Interventions
- Ovitex LPR
- Device
- Lead sponsor
- Foregut Research Foundation
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Lone Tree, Colorado
- Conditions
- Obesity
- Interventions
- Biometric-informed care, Control Arm: Standard Care
- Behavioral
- Lead sponsor
- Jeff Reeves
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Amyloidosis, AL Amyloidosis
- Interventions
- ZN-d5
- Drug
- Lead sponsor
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Denver, Colorado • New Orleans, Louisiana + 2 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Best Practice, Internet-Based Intervention, Questionnaire Administration, Survey Administration
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Johns Creek, Georgia
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 891 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 86 more
- Conditions
- Sickle Cell Disease Without Crisis
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- Alessandra Biffi
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts